Abstract: Belzutifan (PT2977) is a first-in-class, oral hypoxia-inducible factor-2α (HIF-2α) inhibitor approved for the treatment of von Hippel-Lindau (VHL) disease-associated neoplasms, including clear cell renal cell carcinoma (ccRCC), central nervous system (CNS) hemangioblastomas, and pancreatic neuroendocrine tumors (pNETs). By allosterically binding to the PAS-B domain of HIF-2α, belzutifan prevents its dimerization with HIF-1β, thereby inhibiting the transcription of downstream oncogenic targets like vascular endothelial growth factor (VEGF) and erythropoietin. Clinical trials, notably the LITESPARK series, have demonstrated significant and durable objective response rates across various VHL-associated tumors and sporadic ccRCC. While generally well-tolerated, its unique mechanism of action leads to on-target adverse events such as anemia and hypoxia. Current research is focused on overcoming emerging resistance mechanisms, such as the EPAS1 G323E mutation, and exploring combination therapies with tyrosine kinase inhibitors and immune checkpoint inhibitors to enhance its therapeutic efficacy.
1. Introduction
Von Hippel-Lindau (VHL) disease is a rare autosomal dominant genetic disorder caused by germline mutations in the VHL tumor suppressor gene located on chromosome 3p25 [2][6]. Inactivation of the VHL gene leads to the constitutive activation of hypoxia-inducible factors (HIFs), particularly HIF-2α, which drives the transcription of genes promoting angiogenesis, cell proliferation, and tumor growth [3][8]. Patients with VHL disease are highly predisposed to developing multiple hypervascular neoplasms, including clear cell renal cell carcinoma (ccRCC), CNS and retinal hemangioblastomas, pancreatic neuroendocrine tumors (pNETs), and pheochromocytomas/paragangliomas (PPGLs) [2][6][13]. Historically, management relied on repeated surgical interventions and tumor surveillance, which are not curative and carry significant morbidity [6]. The development of belzutifan (PT2977/MK-6482), a potent and selective HIF-2α inhibitor, represents a paradigm shift in the pharmacological management of VHL disease, offering a targeted approach that directly addresses the underlying molecular defect driving tumorigenesis [1][6].
2. Pharmacological Activity
Belzutifan has demonstrated robust clinical efficacy in VHL-associated neoplasms and sporadic ccRCC. The pivotal phase II LITESPARK-004 (MK-6482-004) trial evaluated belzutifan (120 mg daily) in VHL patients with localized ccRCC and other associated tumors [3][6]. The study reported an objective response rate (ORR) of 49% to 67.2% for VHL-associated ccRCC, with a 24-month progression-free survival (PFS) rate of 96% [3][6][8]. Significant responses were also observed in non-RCC lesions, including an ORR of 30-48% for CNS hemangioblastomas, 100% for retinal hemangioblastomas, and 77-91% for pNETs [2][4][5][6]. Pharmacokinetically, belzutifan is primarily metabolized by UGT2B17 and CYP2C19 enzymes. Dual poor metabolizers of these enzymes may experience higher drug exposure, necessitating closer monitoring for adverse reactions [8]. Belzutifan has also shown efficacy in sporadic advanced ccRCC, leading to its approval for patients previously treated with immune checkpoint inhibitors and anti-angiogenic agents, based on the LITESPARK-005 trial which demonstrated superior PFS compared to everolimus [4][8].
3. Molecular Mechanism of Action
Under normoxic conditions, the VHL protein acts as the substrate-recognition component of an E3 ubiquitin ligase complex that targets prolyl-hydroxylated HIF-α subunits for rapid proteasomal degradation [1][8]. In VHL disease or sporadic ccRCC with somatic VHL mutations, the loss of functional pVHL prevents this degradation, leading to the intracellular accumulation of HIF-2α regardless of oxygen availability—a state known as pseudohypoxia [1][8]. Accumulated HIF-2α translocates to the nucleus and heterodimerizes with HIF-1β (also known as aryl hydrocarbon receptor nuclear translocator, ARNT) [1][8]. This HIF-2α/HIF-1β complex binds to hypoxia response elements (HREs) on DNA, driving the transcription of target genes such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and erythropoietin (EPO), which promote angiogenesis, metabolic adaptation, and tumor proliferation [1][8]. Belzutifan functions as a small-molecule allosteric inhibitor that specifically binds to an internal cavity within the PAS-B domain of HIF-2α. This binding induces a conformational change that sterically hinders the dimerization of HIF-2α with HIF-1β, thereby blocking the downstream transcriptional activation of oncogenic targets [1][4][6].
4. Structure-Activity Relationship (SAR)
HIF-2α was long considered "undruggable" because it lacks a traditional enzymatic active site [1][4]. However, the discovery of a lipophilic, ligand-binding cavity within the PAS-B domain of HIF-2α enabled the development of allosteric inhibitors [1][4]. First-generation inhibitors, such as PT2399 and PT2385, successfully demonstrated the proof-of-concept by binding to this pocket and disrupting HIF-2α/HIF-1β dimerization [2][4]. However, PT2385 exhibited suboptimal pharmacokinetics and variable interindividual exposure [1][8]. Belzutifan (PT2977/MK-6482) was subsequently developed as a second-generation inhibitor with structural modifications that conferred approximately ten-fold greater potency, improved selectivity, and a more consistent pharmacokinetic profile compared to its predecessors [1][4][8]. The binding of belzutifan is heavily mediated by key residues, such as M252 of HIF-2α, located near the dimer interface, which destabilizes the complex formation [4].
5. Current Limitations
Despite its efficacy, belzutifan therapy is associated with distinct, on-target adverse events and the potential for acquired resistance. The most common adverse events are anemia (affecting up to 90% of patients) and hypoxia (affecting 16-23% of patients), which directly result from the inhibition of HIF-2α-mediated erythropoietin production and hypoxic ventilatory responses [1][3][6]. These toxicities often require dose modifications, treatment interruptions, or supplemental oxygen [1][7]. Furthermore, acquired resistance to HIF-2α inhibitors has been documented. The primary mechanism involves "gatekeeper" missense mutations in the PAS-B domain, most notably the G323E mutation in the EPAS1 gene (which encodes HIF-2α) [3][8][10]. This mutation alters the binding pocket, preventing belzutifan from binding while preserving the protein's ability to dimerize with HIF-1β [8]. Another identified resistance mutation is F446L in HIF-1β, which increases its binding affinity for HIF-2α, overcoming the allosteric blockade [8]. Other proposed resistance mechanisms include compensatory upregulation of HIF-1α and alterations in the TP53 pathway [10].
6. Future Perspectives
To overcome resistance and enhance efficacy, future strategies are heavily focused on combination therapies. Clinical trials are currently evaluating belzutifan in combination with multi-targeted tyrosine kinase inhibitors (TKIs) like cabozantinib (LITESPARK-003) and lenvatinib (KEYMAKER-U03B, LITESPARK-011), which target downstream angiogenic pathways (VEGFR, MET) and have shown synergistic anti-tumor activity [1][3][4][8]. Combinations with immune checkpoint inhibitors (ICIs) such as pembrolizumab are also being explored (LITESPARK-022, LITESPARK-012), based on evidence that HIF-2α inhibition may reverse the immunosuppressive tumor microenvironment by decreasing PD-L1 expression and reducing immunosuppressive cytokines [4][10]. Additionally, newer generation HIF-2α inhibitors (e.g., casdatifan, NKT2152, DFF332) are in early-phase development and may offer alternative options or overcome specific resistance mutations like G323E [3][4]. Beyond ccRCC and pNETs, belzutifan is being investigated for other VHL-associated manifestations, including advanced pheochromocytomas and paragangliomas (PPGLs), particularly those with pseudohypoxic Cluster 1 mutations, representing a significant expansion of its therapeutic utility [12][13].
